At 38 weeks gestation, should a patient with preeclampsia without severe features be delivered now?

Delivery at 38 Weeks for Preeclampsia Without Severe Features

Yes, deliver now at 38 weeks gestation for preeclampsia without severe features. 1, 2

Evidence-Based Delivery Timing

Delivery at 37-38 weeks gestation is the definitive recommendation for preeclampsia without severe features, regardless of cervical favorability or labor status. 1, 3, 2 The most recent high-quality guidelines uniformly support this approach:

• The 2025 Circulation guidelines state that delivery is recommended for patients presenting with preeclampsia without severe features after 37 weeks of gestation 1
• The 2024 French College of Obstetricians and Gynecologists guidelines (GRADE methodology) provide a strong recommendation to induce birth in women with non-severe preeclampsia diagnosed between 37+0 and 41 weeks of gestation to reduce maternal morbidity 2
• The 2018 International Society for the Study of Hypertension in Pregnancy (ISSHP) guidelines eliminated the "mild vs severe" classification system, instead using "with or without severe features," and recommend delivery at 37-38 weeks for any preeclampsia without severe features 1, 3

Maternal Risk Reduction

Immediate delivery significantly reduces maternal morbidity without increasing cesarean delivery rates or neonatal complications. 4, 5

• The landmark HYPITAT trial demonstrated that induction of labor at ≥37 weeks was associated with lower rates of maternal complications without increased cesarean delivery or adverse neonatal outcomes 4
• Expectant management beyond 37 weeks carries substantial maternal risk: approximately 25% of gestational hypertension cases progress to preeclampsia, and this progression can occur rapidly 3
• Blood pressure level alone does not reliably stratify risk—serious organ dysfunction (HELLP syndrome, renal impairment, eclampsia) can develop even at relatively mild hypertension levels 3, 6

Risks of Expectant Management at Term

Continuing pregnancy beyond 37-38 weeks with preeclampsia exposes the mother to preventable severe complications. 5, 7

• In late preterm patients (34-37 weeks) with preeclampsia without severe features who were expectantly managed, 41% developed severe features within 72 hours 5
• Maternal complications from expectant management include progression to severe hypertension (≥160/110 mmHg), thrombocytopenia, liver dysfunction, renal failure, placental abruption, and eclampsia 1, 6, 7
• The only definitive treatment for preeclampsia is delivery of the placenta; antihypertensive medications merely manage symptoms and do not alter the underlying pathophysiology 1, 6, 7

Delivery Method

Vaginal delivery via induction of labor is preferred unless standard obstetric contraindications exist. 1, 2

• The 2024 French guidelines provide a strong recommendation to perform a trial of labor in the absence of contraindication (very low quality of evidence, but strong consensus) 2
• The 2020 European Society of Cardiology guidelines state that vaginal delivery is preferred unless cesarean is indicated for standard obstetric reasons, and induction of labor is appropriate 1
• Cesarean delivery should be avoided when possible to prevent the added physiologic stress of surgery in a patient with endothelial dysfunction 1

Peripartum Management Essentials

During labor and delivery, implement continuous maternal and fetal monitoring with readiness for acute severe hypertension treatment. 1, 8

Blood Pressure Monitoring

• Continuous or frequent blood pressure assessment throughout labor 8
• Severe hypertension (≥160/110 mmHg) requires urgent treatment within 15 minutes to prevent maternal stroke 1, 3
• First-line acute treatment options: oral nifedipine, intravenous labetalol, or intravenous hydralazine 1

Magnesium Sulfate Prophylaxis

• Administer magnesium sulfate if severe hypertension develops (≥160/110 mmHg) or if neurological symptoms appear (severe headache, visual disturbances, hyperreflexia) 1, 8
• Loading dose: 4-5g IV over 5 minutes, followed by maintenance infusion of 1-2g/hour 3

Fetal Surveillance

• Continuous electronic fetal heart rate monitoring is recommended given the increased risk of placental insufficiency 8

Common Pitfalls to Avoid

Do not delay delivery based on cervical unfavorability or patient preference for spontaneous labor at term. 3, 2 The maternal risks of expectant management outweigh any perceived benefits of awaiting spontaneous labor.

Do not rely solely on blood pressure readings to assess disease severity. 3 Serious complications including HELLP syndrome, renal dysfunction, and eclampsia can develop with relatively modest blood pressure elevations (150/100 mmHg) in previously normotensive women 1

Do not use short-acting sublingual nifedipine for acute severe hypertension. 1 This route causes uncontrolled hypotension, particularly when combined with magnesium sulfate, resulting in fetal compromise 1

Do not attempt expectant management between 34-37 weeks. 2, 5 The 2024 French guidelines provide a strong recommendation (high quality evidence) NOT to systematically induce birth between 34 and 36+6 weeks for non-severe preeclampsia, as this increases moderate prematurity without sufficient maternal benefit 2. However, at ≥37 weeks, the balance shifts decisively toward delivery 2

Postpartum Considerations

Enhanced blood pressure surveillance is required for at least 6 weeks postpartum, with long-term cardiovascular follow-up. 1, 2

• Postpartum preeclampsia can develop or worsen after delivery 1
• Women with preeclampsia have significantly increased lifelong risk of chronic hypertension and cardiovascular disease 2
• Blood pressure and proteinuria should be checked at 6 weeks postpartum, with persistent abnormalities requiring specialist referral 8, 2